Drug recall · September 2, 2020
Buprenorphine HCl Injection recall
Why: Sub-potent Drug: Out-of-Specification assay results found at 3 month stability testing.
Class II: could cause temporary or reversible health problems; serious harm is remote.
The recall
- Product
Buprenorphine HCl Injection, 0.3 mg/mL, 1 mL vial, For Intramuscular or Intravenous Use Only, Rx Only, Manufactured by: Hikma Farmaceutica, Portugal S.A., Distributed by: Hikma Pharmaceuticals, Eatontown, NJ 07724, USA Inc., NDC: 0143-9246-01.
- Lots / codes
Lot #s: 2005023.1, 2005024.1, 2005025.1, Exp 02/28/2021
- Quantity
- 97,890 vials
- Company
- Hikma Pharmaceuticals USA Inc., Cherry Hill, NJ
- Distribution
- Nationwide in the U.S.
- Initiated
- August 14, 2020 · Voluntary: Firm initiated
- Classified
- August 21, 2020
- Reported
- September 2, 2020
- Ended
- June 10, 2021
- How notified
- Letter
The drug: prices, other makers, shortages
If you have this product
- Check the lot number on your package against the lots above. Only those lots are recalled.
- Don't stop a prescription medicine on your own. Call your pharmacy - they can swap it for an unaffected lot or another maker.
- Felt unwell? Contact your doctor, and report it to FDA MedWatch (1-800-FDA-1088 or fda.gov/medwatch).
- Return or dispose of recalled product as the company or your pharmacy advises.
Questions about this recall
No comments yet. Questions, tips, what worked for you - start the conversation.
Watch Buprenorphine
One email when the price moves, a recall or shortage is posted, or the label changes. Plus the monthly biggest-movers report. Unsubscribe in one click.